Literature DB >> 2258577

HLA-DR4 associated response to corticosteroids in Graves' ophthalmopathy patients.

R van der Gaag1, W M Wiersinga, L Koornneef, M P Mourits, M F Prummel, A Berghout, R R de Vries, G M Schreuder, J D'Amaro.   

Abstract

Fifty-seven patients with severe Graves' ophthalmopathy were treated with corticosteroids. Therapeutic outcome was assessed according to predetermined criteria as response (n = 37) or non-response (n = 20) to therapy. Patients were typed for HLA-A, -B, -C, -DR and -DQ. HLA-DR4 was completely absent in the 20 non-responder patients (corrected p value = 0.042). In the responder group 14 of the 37 patients were HLA-DR4 positive. This study shows that in Graves' ophthalmopathy patients the presence of HLA-DR4 is associated with a good response to corticosteroid therapy. The frequency of HLA-DR4 in the Graves' ophthalmopathy population as a whole, however, was not different from normal (25% versus 26%). But as reported previously, the frequency of HLA-DR3 was significantly increased in the Graves' ophthalmopathy patients when compared to healthy blood donors (47% versus 24%, corrected p value = 0.02). No significant deviations were found in the HLA-A, -B, or -C loci.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2258577     DOI: 10.1007/BF03348605

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  21 in total

1.  Do HLA-DR-typing and measurement of TSH-receptor antibodies help in the prediction of the clinical course of Graves' thyrotoxicosis after antithyroid drug treatment?

Authors:  H Schleusener; J Schwander; G Holl; K Badenhoop; J Hensen; R Finke; G Schernthaner; W R Mayr; P Kotulla
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1987

2.  Supervoltage orbital radiotherapy for Graves' ophthalmopathy.

Authors:  S S Donaldson; M A Bagshaw; J P Kriss
Journal:  J Clin Endocrinol Metab       Date:  1973-08       Impact factor: 5.958

3.  Prediction of relapse in hyperthyroid Graves' disease.

Authors:  A M McGregor; B R Smith; R Hall; M M Petersen; M Miller; P J Dewar
Journal:  Lancet       Date:  1980-05-24       Impact factor: 79.321

4.  Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association.

Authors:  S C Werner
Journal:  J Clin Endocrinol Metab       Date:  1977-01       Impact factor: 5.958

Review 5.  The human major histocompatibility complex and endocrine disease.

Authors:  N R Farid; J C Bear
Journal:  Endocr Rev       Date:  1981       Impact factor: 19.871

6.  HLA antigens in Graves' disease.

Authors:  K Bech; B Lumholtz; J Nerup; M Thomsen; P Platz; L P Ryder; A Svejgaard; K Siersbaek-Nielsen; J M Hansen; J H Larsen
Journal:  Acta Endocrinol (Copenh)       Date:  1977-11

7.  Therapeutic outcome of prednisone medication and of orbital irradiation in patients with Graves' ophthalmopathy.

Authors:  W M Wiersinga; T Smit; A L Schuster-Uittenhoeve; R van der Gaag; L Koornneef
Journal:  Ophthalmologica       Date:  1988       Impact factor: 3.250

8.  The pathogenesis of Graves' ophthalmopathy.

Authors:  P Kendall-Taylor
Journal:  Clin Endocrinol Metab       Date:  1985-05

9.  Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach.

Authors:  M P Mourits; L Koornneef; W M Wiersinga; M F Prummel; A Berghout; R van der Gaag
Journal:  Br J Ophthalmol       Date:  1989-08       Impact factor: 4.638

10.  Major histocompatibility complex (MHC) factors predisposing to and protecting against Graves' eye disease.

Authors:  M Frecker; G Mercer; V M Skanes; N R Farid
Journal:  Autoimmunity       Date:  1988       Impact factor: 2.815

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.